^
Association details:
| Biomarker: | KLC1-ROS1 fusion |
|---|---|
| Cancer: | Glioma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma
Excerpt:
We describe a novel KLC1–ROS1 fusion identified in a case of pediatric low-grade glioma.... In vitro analysis demonstrated the oncogenic activity of this fusion, which was suppressed by the ALK/ROS1 inhibitor, crizotinib.
